scholarly journals In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates

1998 ◽  
Vol 42 (2) ◽  
pp. 471-472 ◽  
Author(s):  
M. Hong Nguyen ◽  
Christine Y. Yu
Keyword(s):  
Cryptococcus Neoformans ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Comparative Efficacy ◽  
In Vitro Susceptibility ◽  
In Vitro Susceptibility Testing ◽  
Fluconazole Resistant ◽  
Dose Dependent

ABSTRACT In vitro susceptibility testing for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole. Voriconazole was more potent than itraconazole for fluconazole-susceptible isolates and as potent as itraconazole for fluconazole-susceptible dose-dependent isolates and for fluconazole-resistant isolates. For fluconazole-resistant isolates, the voriconazole and itraconazole MICs ranged from 1 to 2 μg/ml.

scholarly journals In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil

2001 ◽  
Vol 43 (5) ◽  
pp. 267-270 ◽  
Author(s):  
Sydney Hartz ALVES ◽  
Loiva T. OLIVEIRA ◽  
Jane M. COSTA ◽  
Irina LUBECK ◽  
Agnes Kiesling CASALI ◽  
...  
Keyword(s):  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Antifungal Agents ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Environmental Isolates ◽  
Aids Patients ◽  
In Vitro Susceptibility ◽  
Minimal Inhibitory Concentrations

The purpose of the present study was to compare the susceptibility to four antifungal agents of 69 Cryptococcus neoformans strains isolated from AIDS patients with that of 13 C. neoformans strains isolated from the environment. Based on the NCCLS M27-A methodology the Minimal Inhibitory Concentrations (MICs) obtained for amphotericin B, itraconazole and ketoconazole were very similar for clinical and environmental isolates. Clinical isolates were less susceptible to fluconazole than environmental isolates. The significance of these findings and aspects concerning the importance, role and difficulties of C. neoformans susceptibility testing are also discussed.

scholarly journals Fungal Phospholipase Activity and Susceptibility to Lipid Preparations of Amphotericin B

2001 ◽  
Vol 45 (11) ◽  
pp. 3231-3233 ◽  
Author(s):  
Magnus Gottfredsson ◽  
Chad J. Jessup ◽  
Gary M. Cox ◽  
John R. Perfect ◽  
Mahmoud A. Ghannoum
Keyword(s):  
Candida Albicans ◽  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Susceptibility Testing ◽  
Phospholipase Activity ◽  
Lipid Complex ◽  
In Vitro Susceptibility ◽  
Amphotericin B Lipid Complex ◽  
In Vitro Susceptibility Testing

ABSTRACT It has been postulated that phospholipases of fungal origin can affect in vitro susceptibility testing of amphotericin B lipid complex (ABLC). We used specific phospholipase-deficient mutants ofCandida albicans and Cryptococcus neoformans in susceptibility testing and demonstrated that extracellular fungal phospholipase activity does not influence the in vitro susceptibilities of these two fungi to ABLC.

scholarly journals Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0244967
Author(s):  
Nousheen Parvaiz ◽  
Faisal Ahmad ◽  
Wenbo Yu ◽  
Alexander D. MacKerell ◽  
Syed Sikander Azam
Keyword(s):  
Combination Therapy ◽  
Antimicrobial Agents ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
Drug Resistant ◽  
Activity Assay ◽  
Primary Resistance ◽  
In Vitro Susceptibility ◽  
In Vitro Susceptibility Testing

β-lactam antibiotics are the most widely used antimicrobial agents since the discovery of benzylpenicillin in the 1920s. Unfortunately, these life-saving antibiotics are vulnerable to inactivation by continuously evolving β-lactamase enzymes that are primary resistance determinants in multi-drug resistant pathogens. The current study exploits the strategy of combination therapeutics and aims at identifying novel β-lactamase inhibitors that can inactivate the β-lactamase enzyme of the pathogen while allowing the β-lactam antibiotic to act against its penicillin-binding protein target. Inhibitor discovery applied the Site-Identification by Ligand Competitive Saturation (SILCS) technology to map the functional group requirements of the β-lactamase CMY-10 and generate pharmacophore models of active site. SILCS-MC, Ligand-grid Free Energy (LGFE) analysis and Machine-learning based random-forest (RF) scoring methods were then used to screen and filter a library of 700,000 compounds. From the computational screens 74 compounds were subjected to experimental validation in which β-lactamase activity assay, in vitro susceptibility testing, and Scanning Electron Microscope (SEM) analysis were conducted to explore their antibacterial potential. Eleven compounds were identified as enhancers while 7 compounds were recognized as inhibitors of CMY-10. Of these, compound 11 showed promising activity in β-lactamase activity assay, in vitro susceptibility testing against ATCC strains (E. coli, E. cloacae, E. agglomerans, E. alvei) and MDR clinical isolates (E. cloacae, E. alvei and E. agglomerans), with synergistic assay indicating its potential as a β-lactam enhancer and β-lactamase inhibitor. Structural similarity search against the active compound 11 yielded 28 more compounds. The majority of these compounds also exhibited β-lactamase inhibition potential and antibacterial activity. The non-β-lactam-based β-lactamase inhibitors identified in the current study have the potential to be used in combination therapy with lactam-based antibiotics against MDR clinical isolates that have been found resistant against last-line antibiotics.

scholarly journals In Vitro Susceptibility Testing of Clinical Isolates of Chlamydia trachomatis

1993 ◽  
Vol 1 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Mark G. Martens ◽  
Sebastian Faro ◽  
Maurizio Maccato ◽  
Gerald Riddle ◽  
Hunter Hammill ◽  
...  
Keyword(s):  
Chlamydia Trachomatis ◽  
Susceptibility Testing ◽  
Clinical Isolates ◽  
In Vitro Susceptibility ◽  
In Vitro Susceptibility Testing
Sign in / Sign up

Export Citation Format

Share Document